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Abstract
Methylene diphenyl diisocyanate (MDI), the most abundantly produced diisocyanate worldwide, is 
among the best recognized chemical causes of occupational asthma. The bulk of synthesized MDI, 
the 4,4’ isomer, has been the focus of most biochemical research to date. The biological reactivity 
of other MDI isomers (2,2’ and 2,4’), present at concentrations approaching 50% in some 
commercial products, remains less clear. We hypothesized 2,2’ and 2,4’ MDI react with 
glutathione (GSH), a major anti-oxidant of the lower airways, similarly to 4,4’ MDI, and that the 
products could be characterized using a combination of LC-UV-MS and MS/MS. Purified 2,2’ and 
2,4’ MDI isomers were mixed with GSH in pH-buffered aqueous phase at 37°C and reaction 
products were analyzed at varying time points. Within minutes, S-linked bis(GSH)-MDI 
conjugates were detectable as the dominant [M+H]+ ion, with an 865.25 m/z and more intense [M
+2H]2+ ions of the same nominal mass. Upon longer reaction, [M+H]+ ions with greater retention 
times and the 558.17 m/z expected for mono(GSH)-MDI reaction products were observed, and 
exhibited MS/MS collision-induced dissociation (CID)-fragmentation patterns consistent with 
cyclized structures. Compared with 4,4’ MDI, 2,2’ and 2,4’ isomers exhibit similar rapid reactivity 
with GSH and formation of bis(GSH)-MDI conjugates, but greater formation of cyclized 
mono(GSH) conjugates following extended reaction times (10 minutes to 2 hours). Further 
translational studies will be required to determine if the present in vitro findings extend to the 
complex lower airway microenvironment in vivo.
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Introduction
Methylene diphenyl diisocyanate (MDI), the most abundantly produced diisocyanate, is 
widely used in many different industries [1–3]. Inhalation of MDI into the lower airways has 
been reported to cause asthma in hypersensitized individuals and animal models, presumably 
due to chemical modification of “self” molecules in a manner that triggers inflammation [4–
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7]. Crude and technical grade preparations of MDI typically contain > 50% of the 4,4’ 
isomer, which been the focus of most biomedical research to date [3,6,8,9]. However, 
contemporary MDI formulations may also contain other (2,4’ and 2,2’) isomers (some with 
concentrations reaching nearly 50%) [3,10–12], whose biological reactivity remains unclear 
(Figure 1).
One self molecule susceptible to diisocyanate reactivity in vitro and in vivo is the unique 
tripeptide, glutathione (GSH), a major anti-oxidant of the lower airways [13–18]. The 4,4’ 
isomer of MDI exhibits preferential binding to free thiols (as present in GSH) vs. NH2 
groups (present on proteins), and rapidly forms S-linked bis and mono(GSH)-MDI 
conjugates [16,19,20]. In vitro, MDI-GSH conjugates are cleaved into their corresponding 
(cys-gly) conjugates by human gamma glutamyl transpeptidase-1 [21], the primary step in 
metabolism along the mercapturic acid pathway [22]. GSH reacts with aliphatic 
hexamethylene diisocyanate vapors in vivo [18], and protects airway cells against exposure 
in vitro [23]. GSH also reacts with aliphatic (2-cyclohexyl-and 2-chloroethyl-) 
monoisocyanate metabolites of anti-cancer drugs (Lomustine and Carmustine) [24].
The biological reactivity of 2,2’ and 2,4’ isomers of MDI, remains relatively unknown, and 
may differ from that of 4,4’ MDI due to intrinsic differences between isomers. Under 
polyurethane manufacturing conditions (80°C, dry toluene, nitrogen blanket), N=C=O in 
MDI’s para vs. ortho is 3.8 −5.6 times more reactive with alcohols [25]; however, the 
influence of N=C=O’s position (para vs. ortho) in 2,2’ and 2,4’ MDI with biological 
molecules remains unknown. This investigation compared 2,2’ and 2,4’ vs. 4,4’ MDI 
isomers’ reactivity with GSH in aqueous phase at 37°C and neutral pH. A combination of 
LC-UV-MS and MS/MS techniques were employed to identify and compare the GSH 
reaction products with the different MDI isomers.
Materials and Methods
Reactivity of different MDI isomers with GSH
Purified 2,2’ MDI (CAS# 2536–05-02/Desmodur 22M), 2,4’ MDI (CAS# 5873–54-1/
Desmodur 24MI) and 4,4’ MDI (CAS# 101–68-8/ Desmodur 44M) were obtained from the 
International Isocyanate Institute (Boonton, New Jersey). Purity was certified by GC-MS 
(98.54%, 99%, and 98.6% for 2,2’, 2,4’ and 4,4’ MDI respectively). Each isomer of MDI 
was initially diluted in extra dry 99.8% acetone (≤ 0.005% water) manufactured by Acros 
Organics (Morris Plains, NJ) to achieve a 10% weight/volume (w/v) stock solustion. MDI 
stock solutions were prepared within minutes of use for each experiment, and further diluted 
100-fold in HPLC grade water buffered to pH 7.4 with 200 mM sodium phosphate (JT 
Baker; Center Valley, PA) containing 20 mM reduced glutathione (GSH) from Sigma-
Aldrich (St. Louis, MO). Reaction conditions were based on prior published studies of GSH 
reactivity with 4,4’-MDI, containing a slight (2.5:1) molar excess of GSH’s reactive SH to 
MDI’s N=C=O groups to drive the reaction forward [19,26].
Reaction solutions were immediately vortexed and then incubated with end-over-end 
rotation (15 rotations/minute) for varying time periods ranging from 1 minute to 2 hours. 
GSH solutions were pre-equilibrated to 37°C and all experiments were performed in a 37°C 
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temperature regulated room. Following varying durations of reactivity, samples were 
immediately filtered, mixed 1:10 with water/0.1% formic acid (to stabilize thiocarbamate 
linkages and prepare for LC-MS), stored at 4°C and analyzed within 2 hours, or stored at 
−80°C. Prior to analysis all samples were microfuged (16,000g) before transfer to LC-MS 
vials. All experiments were repeated on three different days with fresh reagents and included 
control reactions without GSH or MDI [26].
LC-UV-MS and MS/MS analysis of MDI-GSH reaction products
Reaction products of different MDI isomers with GSH were assessed through LC-MS/MS 
using a C18 LC column and electrospray ionization (ESI) in positive mode, with an 
increasing gradient of acetonitrile for elution. Samples were analyzed on an Agilent G6550A 
QTOF system coupled to an Agilent 1290 Infinity LC system, using a rapid resolution HT 
Zorbax Eclipse Plus C18 column (2.1 × 50 mm, 1.8 μm) from Agilent Technologies (Santa 
Clara, CA).
Samples (5 μL) were loaded and eluted over a 5 minutes period starting at time 0 with a 98:2 
ratio of water:acetonitrile, increasing to 85:15 between 0 and 1 minute, 60:40 between 1 and 
3 minutes, 5:95 between 3 and 4 minutes, up to 2:98 by 4.5 minutes and held till 5 minutes. 
All water and acetonitrile solutions contained 0.1% formic acid. Positive electrospray 
ionization (ESI+) was performed using the following parameters: gas temperature-280°C, 
gas flow-11 l/min, nebulizer-40 psig, sheath gas temp-350°C, sheath gas flow-11, 
Vcap-4000V, nozzle voltage-2000 V, fragmentor voltage-175V, skimmer voltage 65V, 
octopole RF peak voltage 750 V. The m/z values of all ions present in the mass spectra were 
corrected against two reference ions (purine, [M +H]+ m/z 112.9856 and 1H, 1H, 3H 
tetra(fluoropropoxy) phosphazene, [M+H]+ m/z 922.0097). The data acquisition range for 
LC-MS was from 110 to 1700 m/z. UV light absorbance (210, 254 nm) coupled to LC-MS 
was captured by diode array detection.
For MS/MS analyses, the collision energy was automatically set using Agilent MassHunter 
Acquisition software according to the formula, slope x (m/z)/100 + offset; with the slope of 
5 and offset of 2.5. MS/MS data were obtained for the 5 most intense ions, in some 
experiments with preference given to species of interest with m/z’s of 865.25, 558.17, 
532.12, 199.12, or 106.06 ± 100 ppm. Data were acquired and analyzed using MassHunter 
Workstation software from Agilent.
Data Analysis
New reaction products were identified by comparison of experimental samples’ total ion 
chromatograms (TICs), base peak chromatograms (BPCs), and chromatograms of ultraviolet 
(UV) light absorbance (at 210, 254 nm) versus control reactions performed without GSH or 
MDI. Extracted ion chromatograms (EICs) for [M+H]+ ions with defined m/z values and 
peak identification were accomplished with MassHunter Software. ChemDraw Professional 
16.0 (PerkinElmer; Branford, CT) was used for chemical structure modelling, based on the 
exact mass of newly formed products (e.g. [M+H]+ ions), and their MS/MS fragmentation 
pattern upon CID.
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Results
Primary reaction product of 2,2’ and 2,4’ MDI isomers with GSH
When purified 2,2’ and 2,4’ MDI isomers were incubated with GSH under at 37°C in 
aqueous phase at pH 7.4, a prominent new product was readily identified by comparing TICs 
of experimental vs. control reactions performed without MDI. Within 1 minute (Figure 2), 
this primary reaction product was distinguishable as an [M+H]+ ion with an 865.25 m/z and 
a more intense [M+2H]2+ ion (433.12 m/z), consistent with that previously described for 
bis(GSH)-MDI products with 4,4’ MDI [21]. The different isomers’ bis(GSH)-MDI reaction 
products had slightly different retention times on the C18 LC column; those comprised of 
2,2’ MDI < 2,4’ MDI < 4,4’ MDI under the reverse phase chromatography conditions 
employed.
MS/MS CID produced fragments of the 865 m/z [M+H]+ ion derived from reaction of 2,2’ 
and 2,4’ MDI with GSH, are shown in figure 3, and support the structures proposed in figure 
4. Daughter ions of the 865.25 m/z [M+H]+ parent ion include a 607 m/z [M+H]+ ion 
characteristic of S,S’-linked bis(GSH)-MDI (See supplemental materials, figure 15). The 
847.24 m/z daughter ion likely results from loss of water (~18 amu) from the 865.25 m/z [M
+H]+ parent ion, while the 790.22 m/z [M+H]+ daughter ion likely results from loss of the 
glycine residue. The 736 m/z daughter ion is consistent with loss of a single γ-glu from 
bis(GSH)-MDI, and the 661.18 m/z daughter ion with fur-ther loss of gly. The 540.16 m/z 
[M+H]+ daughter ion likely results from loss of water and one glutathione moiety from the 
parent 865 m/z [M+H]+ ion. The 429.12 and 483.13 m/z daughter ions are consistent with 
fragmentation of the S-cys linkage of one GSH and subsequent loss of γ-glu or gly from the 
2nd GSH group S-linked to MDI. The prominent 326.097 m/z daughter ion is consistent with 
a fragment con-taining the cysteine group of GSH linked to MDI cleaved between the N-C 
bond of MDI’s other N=C=O group. The dominant 179 m/z and the 233.06 daughter ions 
are expected for the cys-gly and γ-glu-cys fragments from GSH. Daughter ions expected 
from fragmented MDI, of 225.10 and 199.12 m/z, were also observed.
The MS/MS fragmentation pattern of 2,2’ and 2,4’ bis(GSH)-MDI are nearly identical to 
that of bis(GSH)-MDI generated from 4,4’ MDI in prior reports [19] and in head-to-head 
experiments in this study (See Figure 6). Thus, 2,2’ and 2,4’ MDI react rapidly with GSH at 
37°C in pH buffered solution. Their primary reaction products are S-linked bis(GSH)-MDI 
conjugates, similar to those previously described with 4,4’ MDI [16].
Bis(GSH)-MDI formation with different MDI isomers followed by UV light absorbance
The amount of bis(GSH)-MDI reaction products formed over time, with 2,2’, 2,4’ and 4,4’ 
MDI isomers, were measured based on UV light absorbance at two different wavelengths; 
210 nm (generally reflective of peptide bonds) and 254 nm (generally reflective of MDI’s 
ring structures) [25,27,28]. The data demonstrate qualitatively similar (increasing) formation 
of bis(GSH)-MDI conjugates with each of the different MDI isomers within the first 6 
minutes of reaction (Figure 7). Quantitation of reaction rates, however, was not possible as 
extinction coefficients for the different MDI isomers’ bis(GSH) conjugates are unknown and 
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likely differ substantially at different UV light wavelengths, based on studies by Nagy., et al. 
of alcoholic derivatives of 2,4’ vs. 4,4’ MDI [25].
Qualitative differences between MDI isomers reaction products with GSH over extended 
reaction times
LC-UV(A210 nm)-MS analysis of GSH reaction products with MDI following extended 
reaction times (10 minutes to 2 hours) revealed unexpected qualitative differences between 
isomers (Figure 8). Reactions with the 2,4’ and 2,2’ vs. the 4,4’ isomer of MDI resulted in 
greater amounts of 558.17 m/z [M+H]⁺ ions than bis(GSH)-MDI.
Notably 2,2’ MDI resulted in one, while 2,4’ MDI reactions resulted in two, major new 
peaks of 558.17 m/z [M+H]+ ions following 2 hr reactions. MS/MS analyses of the 558.17 
m/z [M+H]+ ions (Figure 9 and Figure 10) are consistent with cyclized mono(GSH)-MDI 
(Figure 11), in which the free thiol (cys side chain) and amino terminus (γ-glu) of GSH bind 
a single MDI, as previously described [19]. MS/MS CID fragments of the 558.17 m/z [M
+H]+ ion include 483.13 m/z and 429.12 m/z daughter ions consistent with loss of gly or γ-
glu, as well as 225.10, 199.12, and 106.07 m/z daughter ions consistent with fragmentation 
of MDI, and the 179 m/z cys-gly fragment of GSH. The fragmentation pattern of the 558 
m/z [M+H]+ ions (from 2,4’ MDI-GSH) with shorter retention times displayed qualitative 
differences compared to those with longer retention times and those derived from 2,2’ MDI 
(Figure 9). Further comparison of MS/MS CID fragmentation spectra for 558 m/z [M+H]+ 
ions generated upon reaction of GSH with 4,4’ vs 2,2’ and 2,4’ MDI are provided in (Figure 
12).
The rationale for bis(GSH)-MDI and cyclized mono(GSH)-MDI products with multiple 
retention times remains unclear, and may represent different conformers of the same 
molecule, or structural differences. Evidence for the presence of S,N’-as well as S,S’-linked 
bis(GSH)-MDI following 2 hr reactions of GSH with 2,2’ MDI is supported by the presence 
of a 380.12 m/z daughter ion (consistent with that expected γ-glu-MDI) upon MS/MS 
analysis of a peak eluting with a longer retention time (Figure 13). Reciprocal conjugation of 
GSH’s NH2 and SH moieties to 2,4’ MDI’s ortho vs. para N=C=O groups explain the 
presence of 558.17 m/z [M+H]+ ions with two distinct retention times most evident 
following 2 hr reactions (Figure 8 and 11).
Discussion
This study utilized LC-UV-MS and MS/MS approaches to provide new information on 
biological reactivity of different MDI isomers, which may be influenced by proximity of 
their N=C=O groups to the molecule’s methylene bridge. The present investigation focused 
on the reactivity of 2,2’ and 2,4’ MDI with GSH, a major anti-oxidant of the lower airways, 
and found marked similarities with that previously described for 4,4’ MDI [16,19,26]. Under 
the present experimental conditions (aqueous phase, pH 7.4, 37°C) 2,2’, 2,4’ and 4,4’ MDI 
form primarily bis(GSH)-MDI conjugates within minutes. However, following longer 
reaction times (≥ 10 minutes), 2,2’ MDI and 2,4’ MDI form greater amounts of 
mono(GSH)-MDI, in a form likely stabilized by cyclization [19]. LC-UV-MS and MS/MS 
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approaches facilitated characterization of the 2,2’ and 2,4’ MDI isomers’ reaction products 
with GSH and comparison with those of 4,4’ MDI.
The initially formed bis(GSH)-MDI conjugates with 2,2’ and 2,4’ MDI have longer 
retention times than GSH (on a C18 column under reverse phase conditions) and are readily 
distinguishable as a dominant new peak in LC-UV chromatograms at 210 and 254 nm. 
These bis(GSH)-MDI reaction products are also readily apparent in corresponding LC-MS 
TICs as [M+H]+ ions with an 865.25 m/z and as higher intensity [M+2H]2+ ions of the same 
nominal mass. Upon MS/MS, the different isomers’ primary bis(GSH)-MDI products 
exhibited similar CID-fragmentation patterns, including a daughter ion (607 m/z) that 
differentiates S,S’ vs. potential S,N’-or N,N’-linked conjugates. The primary bis(GSH)-MDI 
products of 2,4’ MDI have a slightly longer retention time than those for 2,2’ MDI, but a 
slightly shorter retention time than those of 4,4’ MDI under reverse phase chromatography 
conditions on a C18 column. Bis(GSH)-MDI reaction products that form following longer 
reaction times (2 hr) exhibit multiple retention times, which may reflect different 
conformations of the same molecule or intramolecular (S-N) rearrangements (as mentioned 
in Section 3C and below).
Cyclized mono(GSH)-MDI conjugates (Figure 8) are possible if GSH’s amino terminus (γ-
glu) and its free thiol (side chain of cysteine) both react with a single MDI. Molecules with 
these properties are distinguishable in LC-MS TICs and BPCs as [M+H]+ ions possessing a 
558.17 m/z and distinct CID fragmentation pattern upon MS/MS, as previously described 
[19]. These conjugates form to varying degrees with 2,2’, 2,4’ and 4,4’ MDI, have longer 
retention times than bis(GSH)-MDI, and may elute at multiple retention times under the 
described reverse phase LC-MS conditions. The biologic relevance of cyclized mono(GSH)-
MDI vs. bis(GSH)-MDI is unknown. However, if cyclization provides stability, as shown for 
some biologically active peptides [29], it could reduce transcarbamylating potential and 
thus, lower antigenicity and toxicity.
The present report focuses on soluble MDI-GSH reaction products that were quantitatively 
most abundant, based on UV-light absorbance, however additional products were also 
present. A precipitate was observed in longer (2 hour) reactions of MDI with GSH solutions, 
possibly polyureas, as previously described for MDI in aqueous phase [30]. The precipitate 
was insoluble in water or organic solvents and thus, could not be analysed by LC-MS, but 
may be characterized in future studies using solid state analytical methods (FTIR, NMR). 
MDI-GSH reactions also contained low levels of GSH-conjugated to partially hydrolyzed 
MDI (GSH-MDI*NH2) not detectable based on UV-light absorbance, but readily apparent in 
LC-MS TICs, exclusively with 2,4’ and 4,4’, but not 2,2’ MDI (see figure 14). In contrast, 
complete hydrolysis products of 2,2’, 2,4’ and 4,4’ MDI were below the limit of detection 
(0.03 μM; e.g. ≤ 0.001% of starting material) defined using purified methylene diamine 
isomer standards (see supplemental materials, figure 15 and Supplemental Methods).
The potential derivation of mono(GSH)-MDI (in cyclized form, or containing partially 
hydrolysed MDI) via intra-or inter-molecular rearrangement of bis(GSH)-MDI (vs. direct 
reactivity of GSH with MDI) is a provocative hypothesis suggested by the order of product 
formation in this study (e.g. mono(GSH)-MDI*NH2 observed only at the latest time points, 
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and cyclized forms increasing over time). The finding are consistent with prior studies on 
4,4’ MDI by Reisser., et al. [16], which suggest dynamic formation of mono(GSH)-MDI 
secondary to bis(GSH)-MDI formation. Further studies with purified bis(GSH)-MDI 
prepared with different MDI isomers should yield more definitive insight into the temporal 
order of bis vs. mono GSH-MDI reaction product formation.
The present data should be interpreted with recognition of the studies strengths and 
weakness. The strengths of the study include the precise methodology for separation of 
reaction products and determination of their mass, availability of purified MDI isomers, and 
the controlled in vitro study design. Conversely, our reductionist in vitro system possesses 
recognizable limitations towards understanding complex interactions that may occur in vivo. 
While we replicated normal body pH, temperature and relative ratios of reactants and 
organic solvent, our in vitro reactions didn’t include a multitude of other factors in the 
airway microenvironment (e.g. surfactant, proteins, GSH-dependent enzymes) that may 
influence MDI reactivity in vivo. Nonetheless, together with prior reports on other 
diisocyanates [17,18,20,31,32], the present data support the concept that GSH in airway 
fluid represents a likely target for 2,2’ and 2,4’, as well as the 4,4’ isomer of MDI.
Conclusion
In summary, we demonstrate similarities and differences in the reactivity of different 
isomers of MDI with GSH, a major anti-oxidant of the lower airways. The three MDI 
isomers studied (2,2’, 2,4’ and 4,4’) all react rapidly with GSH, forming bis(GSH)-MDI 
conjugates within minutes. Following longer reaction times (10 minutes to 2 hours) 2,2’ and 
2,4’ MDI form greater amounts of cyclized mono(GSH)-MDI compared to 4,4’-MDI. 
Further studies will be required to determine if similar GSH reactivity with different MDI 
isomers occurs in the lower airways of exposed workers, and if so, the implications with 
respect to MDI toxicity and allergenicity.
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CID Collision Induced Dissociation
EIC Extracted Ion Chromatogram
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Figure 1. 
Three different isomers of MDI.
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Figure 2. 
Primary reaction product of glutathione with different isomers of MDI. Left: LC-MS TIC’s 
of reactions of glutathione without MDI (A), or with 2,2’ (B), 2,4’ (C) or 4,4’ (D) MDI for 1 
minute. Y-axis represents ion intensity and X-axis represents LC retention time in minutes. 
Right: MS of products (Y-axis = ion intensity and X-axis depicts m/z) with LC retention 
times shown by the arrows in Panels B, C, and D are shown in Panels E, F, and G 
respectively for GSH with 2,2’, 2,4’ and 4,4’ MDI. GSH and GSSG represent glutathione in 
its reduced and oxidized states respectively, while cys-gly, a high intensity ion, is a minor 
contaminant of GSH.
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Figure 3. 
MS/MS analysis of new 865 m/z [M+H]+ product of different MDI isomers with GSH. The 
major new [M+H]+ ion with an 865 m/z was subjected to LC-MS/MS. Fragmented daughter 
ions are shown from the major new 865 m/z [M+H]+ parent ion observed in reactions of 
GSH with 2,2’ MDI (Panel A) or 2,4’ MDI (Panel B). The Y-axis reflects ion intensity and 
the X-axis depicts m/z. Daughter ions detailed in the text are highlighted by arrows. 
Comparison with 4,4’ MDI reactions are shown in Fig. 6.
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Figure 4. 
Proposed chemical structures for bis(GSH)-MDI reaction products formed with 2,2’ or 2,4’ 
MDI. The primary reaction products 2,2’ and 2,4’ MDI form with GSH are modeled based 
on the 865.25 m/z of the parent molecule and its CID fragmentation pattern during LC-
MS/MS shown in figure 3. Theoretical chemical formulas and exact mass provided beneath 
the structures are the same for both compounds.
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Figure 5. 
Predicted MS/MS CID fragments of bis(GSH)-MDI.
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Figure 6. 
MS/MS analysis of 865 m/z [M+H]+ product of GSH with different MDI isomers: 2,2’ (A), 
2,4’ (B), 4,4’ (C).
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Figure 7. 
LC-UV light chromatograms of GSH reaction products with different MDI isomers 
following 1, 3, and 6 minute reactions. A. Entire LC-UV (A210) chromatogram, B. Limited 
region of the LC-UV (A210) chromatogram, and C. Limited region of the LC-UV (A254) 
chromatogram highlighting time frame (~1.9 to 2.8 min) when bis(GSH)-MDI elutes. 
Samples were analyzed following GSH reactivity without MDI (blue), or with 2,2’ (green), 
2,4’ (red), or 4,4’ (black) MDI. Y-axis represents UV light absorbance and X-axis represents 
LC retention time in minutes. Samples following 1, 3 and 6 minutes are shown as labeled.
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Figure 8. 
Differences between MDI isomers following extended reaction times with GSH. The LC-
UV (A210) chromatograms are shown for reactions of GSH with 2,2’ (A), 2,4’ (B) or 4,4’ 
(C) MDI for 10 minutes (top row) or 2 hr (bottom row). Peaks with [M+H]+ ions that 
possess m/z’s corresponding to bis (865 m/z) or mono(GSH)-MDI (558 m/z) reaction 
products are highlighted. *Note 1 peak for mono(GSH)-MDI from 2,2’ MDI, two peaks for 
mono(GSH)-MDI from 2,4’ MDI, and much lower level dual peaks for mono(GSH)-MDI 
with 4,4’ MDI.
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Figure 9. 
LC-MS and MS/MS analysis of new 558 m/z [M+H]+ product formed when GSH reacts 
with 2,2’ and 2,4’ MDI. LC-MS analyses of the major new [M+H]+ ions in A210 
chromatograms are shown on the left for reactions of GSH with 2,2’ MDI (A) and for two 
different peaks formed with 2,4’ MDI (B longer retention time and C shorter retention time). 
During LC-MS/MS, the major reaction products with the 558 m/z [M+H]+ (e.g. parent ions) 
from Panels A - C yielded the corresponding daughter fragments shown in Panels D though 
F respectively, and detailed further in Figure 10. Comparison of the mono(GSH)-MDI 558 
m/z [M+H]+ ions from 2,2’ and 2,4’ vs. 4,4’ MDI (in head-to-head experiments) are shown 
in Figure 12.
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Figure 10. 
Predicted MS/MS CID fragments of mono(GSH)-MDI.
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Figure 11. 
Proposed chemical structures for mono(GSH)-MDI reaction products with a 558 m/z [M+H]
+. The major GSH reaction products that form following extended reaction times (10 
minutes to 2 hours) with 2,2’ and 2,4’ MDI are modeled based on LC-MS/MS CID 
fragmentation patterns shown in Figure 9. Note 2 chemically distinct reaction products are 
proposed for 2,4’ MDI depending upon which N=C=O group (ortho vs. para position) is 
bound to GSH’s NH2 vs. SH moiety. Theoretical chemical formula and exact mass provided 
beneath structures are the same for each compound.
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Figure 12. 
MS/MS analysis of 558 m/z [M+H]+ product of different MDI isomers with GSH. During 
LC-MS/MS, upon CID@30.5eV the 558 m/z parent ions yield the following spectra if 
generated from 2,2’ MDI (Panel A), 2,4’ MDI, Panel B major peak (longer retention), Panel 
C minor peak (shorter retention time), and 4,4’ MDI (Panels D and E, later and earlier 
eluting peaks respectively).
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Figure 13. 
MS/MS comparison of peaks with different retention times but identical 865.25 m/z in 
reactions of 2,4’ MDI with GSH. Fol-lowing 2 hr reaction of 2,4’ MDI with GSH, two 
prominent peaks in the A210 chromatogram were observed with the same (865.25) m/z. 
MS/MS analysis of the 865 m/z [M+H]+ ion with the longer retention time, appearing only 
at the later time points is shown in Panel A and contrasted the CID of the 865 m/z [M+H]+ 
ion with the shorter retention time appearing at the earliest time points. Note the 380.125 
m/z daughter ion that would arise as a γ-glu-MDI fragment from an N-linked MDI 
conjugate, as well as the 607 m/z fragment indicative of S,S’-linked bis(GSH)-MDI, 
suggesting the possibility of mixed reaction products eluting with the same retention time, or 
potential on column rearrangement.
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Figure 14. 
LC-MS TIC of GSH reaction products following extended (2hr) reaction time with different 
MDI isomers. (A) Reactions performed with 2,2’ MDI, (B) Reactions performed with 2,4’ 
MDI, (C) Reactions performed with 4,4’ MDI. Solid thick blue line represents samples 
without MDI (control), while thin red line depicts signal from samples with different MDI 
isomer. Note the [M+H]+ ion with the 532 m/z consistent with previously described 
mono(GSH)-MDI*NH2, a conjugate of GSH with partially hydrolyzed MDI (amine 
terminated), as previously described with 4,4’ MDI [19, 21], is present in reactions with 4,4’ 
and 2,4’ MDI but not 2,2’ MDI.
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